BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9849475)

  • 1. Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.
    Marth C; Tropé C; Vergote IB; Kristensen GB
    Eur J Cancer; 1998 Jul; 34(8):1175-80. PubMed ID: 9849475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study.
    Bertelsen K; Bastholt L
    Gynecol Oncol; 1992 Jan; 44(1):79-82. PubMed ID: 1730430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
    Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma.
    Böhm S; Oriana S; Spatti G; Di Re F; Breasciani G; Pirovano C; Grosso I; Martini C; Caraceni A; Pilotti S; Zunino F
    Oncology; 1999; 57(2):115-20. PubMed ID: 10461057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain.
    Hidalgo M; Mendiola C; López-Vega JM; Castellano D; Mendez M; Batiste-Alenton E; López-Brea M; Belon J; Batista JN; Cortés-Funes H
    Cancer; 1998 Aug; 83(4):719-25. PubMed ID: 9708936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
    Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
    Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
    Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S
    J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
    McGuire WP; Hoskins WJ; Brady MF; Homesley HD; Creasman WT; Berman ML; Ball H; Berek JS; Woodward J
    J Clin Oncol; 1995 Jul; 13(7):1589-99. PubMed ID: 7602348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.